Price
No data yet.
Social Signal Score
Revenue
$48.10M+872.23%Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $222.26M | $-534.11M | $-6.55 |
| 2024 | $171.32M | $-806.74M | $-12.84 |
| 2023 | $134.09M | $-831.72M | $-15.83 |
| 2022 | $154.53M | $-611.13M | $-13.60 |
| 2021 | $33.88M | $-548.28M | $-12.33 |
Valuation
HNSBFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsprnewswire.com·5h ago·Neutral
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). "This first commercial living donor transplant patien
View source ↗
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.60 per share
Typical surprise -33.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 22$-0.26 vs $-0.03miss
- Thu, Apr 23$-0.20 vs $-0.15miss
- Wed, Feb 11$-0.18 vs $-0.17miss
- Thu, Oct 30$-0.19 vs $-0.18miss
- Thu, Jul 17$-0.26 vs $-0.17miss
- Thu, Apr 24$-0.05 vs $-0.27beat
Estimates and results for HNSBF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.